You just read:

Janssen Submits Supplemental New Drug Application to U.S. FDA for SPRAVATO® (esketamine) CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Oct 02, 2019, 16:03 ET